Mortality associated to late-onset hypogonadism: Reasons not to treat with testosterone?

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1161-1163

  Kaufman, Jean Marc ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

AGING; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANGIOCARDIOGRAPHY; ASYMPTOMATIC DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE SEVERITY; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); TESTOSTERONE BLOOD LEVEL;

AGING; HUMANS; HYPOGONADISM; MALE;

EID: 84898414841     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1103     Document Type: Review

References (20)

1. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005; 26:833-876.
2. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96: 2430-2439.
3. Sartorius G, Spasevska S, Idan A, et al. Serum testosterone, dihy-drotestosterone and estradiol concentrations in older men self-reporting very good health: the Healthy Man Study. Clin Endocrinol (Oxf). 2012;77:755-763.
4. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95: 2536-2559.
5. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92: 4241-4247.
6. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363:123-135.
7. Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of an-drogen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab . 2012; 97:1508-1516.
8. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008; 159:507-514.
9. Wu FC. Caveat emptor: does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab. 2012;97:1884-1886.
10. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96:2341-2353.
11. Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endo-crinol Metab. 2013;98:4300-4310.
12. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007-3019.
13. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687-701.
14. Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. JClin En-docrinol Metab. 2014;99:E9-E18.
15. Pye SR, Huhtaniemi IT, Finn JD, et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab. 2014;99: 1357-1366.
16. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58:1378-1385.
17. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
18. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363: 109-122.
19. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050-2058.
20. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.